FIGURE LEGENDS
Figure 1. CSF and serum levels of PRXs in patients No
significant differences in the CSF levels of peroxiredoxins (PRXs) were
identified among patients with multiple sclerosis (MS) (n = 16),
neuromyelitis optica spectrum disorder (NMOSD) (n = 16), and other
neurological disorders (ONDs) (n = 15). Serum PRX5 and PRX6 levels were
significantly elevated in patients with MS (n = 10) and NMOSD (n = 10)
compared with patients with ONDs (n = 10). Dashed lines indicate mean
values. *P < 0.05; **P < 0.01.
Figure 2. Pathological findings of the EAE spinal
cords Hematoxylin and eosin (HE), glial fibrillary acidic protein
(GFAP), and peroxiredoxins (PRXs) immunoreactivity in the spinal cords
of normal (A) and experimental autoimmune encephalomyelitis (EAE) mice
(at day 18) (B: lower magnification, C: higher magnification) were
performed (n = 2 in each group, representative images are shown).
Inflammation and PRX5 staining were remarkable in EAE mice but not in
normal mice. Black blank squares indicate the area of high
magnification. Bars indicate 100 μm.
Figure 3. Immunofluorescent staining of the EAE spinal cords (A,
B): Peroxiredoxin 5 (PRX5) (red), CD3/CD45 (green), and DAPI (blue)
staining of the spinal cords of experimental autoimmune
encephalomyelitis (EAE) (representative images are shown). PRX5 and
CD45+ cells were confirmed in EAE spinal cords but CD3 positive cells
were not identified. (C): Merged images of PRX5 and CD45 (yellow) and
PRX5 and DAPI (purple). PRX5 was expressed in CD45+ cells. White blank
squares indicate the area of high magnification. Bars indicate 100 μm.